Summary of ceftaroline fosamil clinical trial studies and clinical safety.

Title

Summary of ceftaroline fosamil clinical trial studies and clinical safety.

Creator

File Thomas M Jr; Wilcox Mark H; Stein Gary E

Publisher

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Date

2012
2012-09

Description

In October 2010, the new cephalosporin, ceftaroline fosamil, was approved by the US Food and Drug Administration for therapy of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs). The active metabolite, ceftaroline, demonstrates in vitro activity against typical bacterial pathogens most often associated with CABP or ABSSSIs, including resistant Gram-positive pathogens such as multidrug-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus. The efficacy and safety of ceftaroline fosamil was assessed in 2 large phase 3 programs of randomized, double-blind, clinical trials for CABP and ABSSSIs. For both indications, therapy with ceftaroline fosamil was observed to be noninferior to the comparator agents (ceftriaxone for CABP and vancomycin plus aztreonam for ABSSSIs) at both a standard test of cure assessment time (8-15 days after discontinuation of study drug) and an early assessment time point (day 3 or 4 of study). In the integrated analysis of the trials for CABP (FOCUS 1 and 2), clinical cure rates for the ceftaroline group were numerically higher than those for the ceftriaxone group (for the clinically evaluable population 84.3% vs 77.7%; difference: 6.6%; 95% confidence interval, 1.6%-11.8%). Among patients with CABP caused by S. pneumoniae, clinical cure rates were markedly higher in the ceftaroline treatment group than in the ceftriaxone treatment group (59 of 69 [85.5%] vs 48 of 70 [68.6%], respectively). For the ABSSSI studies (CANVAS 1 and 2), microbiologically evaluable (ME) success rates were similar between the treatment groups. Notably, the clinical cure rates in ME patients with methicillin-resistant S. aureus ABSSSIs were 142 of 152 (93.4%) and 115 of 122 (94.3%), for ceftaroline and vancomycin plus aztreonam, respectively, and did not differ from those achieved in infections due to methicillin-susceptible S. aureus (93.0%-94.5%). Ceftaroline fosamil was well tolerated, with a safety profile similar to the comparator agents used in these phase 3 trials.

Subject

Anti-Bacterial Agents/adverse effects/*therapeutic use; Bacterial/drug therapy; Cephalosporins/adverse effects/*therapeutic use; Clinical Trials as Topic; Humans; Pneumonia; Staphylococcal Skin Infections/drug therapy

Identifier

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

S173–180

Volume

55 Suppl 3

Citation

File Thomas M Jr; Wilcox Mark H; Stein Gary E, “Summary of ceftaroline fosamil clinical trial studies and clinical safety.,” NEOMED Bibliography Database, accessed October 21, 2021, https://neomed.omeka.net/items/show/4174.

Social Bookmarking